Search

everythinglearnresearchcommunity

for

Search:↓

Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.

Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.

No effective treatment for frontal fibrosing alopecia was found, but oral 5-alpha-reductase inhibitors had the best response; for lichen planopilaris, topical corticosteroids were commonly used but had a high relapse rate.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.

Collagen VII helps skin heal and stay strong, sirolimus may lower skin cancer risk in kidney transplant patients, high-molecular-mass hyaluronan helps naked mole rats resist cancer, dermal γδ T cells aid in hair growth in rodents, and overexpression of IL-33 in mouse skin causes itchiness, offering a model for studying allergic inflammation treatments.

Targeted cancer therapies often cause serious skin problems that need careful management.

Lupus affects the body and skin, causing joint pain and skin issues that can be treated with steroids and antimalarial drugs.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Skin problems from transplant drugs are common and need careful management in organ transplant patients.

Chemotherapy and radiotherapy can cause skin side effects like rashes, hair loss, and nail changes, which are usually managed with conservative treatments.

Skin problems are common in Lupus patients and can indicate the disease's severity, requiring specific treatments and lifestyle changes.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Topical treatments like minoxidil and corticosteroids are effective for hair loss, with JAK inhibitors promising for alopecia areata.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.

Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.